Amivantamab (Rybrevant)
Bispecific monoclonal antibody (EGFR/MET-directed antineoplastic)
Amivantamab (Rybrevant)
Forms and strengths
Form: TabletStrength: 350 mg/7 mL (50 mg/mL) single-use vial
References
Indication
- Amivantamab, combined with lazertinib, is used as first-line treatment for advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR exon 19 deletion or exon 21 L858R substitution mutations.
- Amivantamab, combined with carboplatin and pemetrexed chemotherapy, is used for NSCLC with EGFR exon 19 deletion or exon 21 L858R mutations that has progressed after osimertinib treatment.
- Amivantamab, combined with carboplatin and pemetrexed, is used as first-line treatment for NSCLC with EGFR exon 20 insertion mutations.
- Amivantamab, used alone, is used for NSCLC with EGFR exon 20 insertion mutations that has progressed after platinum-based chemotherapy.
- Tumor tissue must be tested and confirmed to carry the relevant EGFR mutation before starting treatment.
Pregnancy
- Amivantamab has not been studied in pregnant women, but based on its mechanism of blocking EGFR and MET, it could cause fetal harm.
- Amivantamab should be avoided during pregnancy unless the benefit to the mother clearly outweighs the risk to the fetus.
- Women of childbearing potential should use effective contraception during treatment and for 3 months after the last dose.
- Men with partners of childbearing potential should use effective contraception and avoid donating or storing semen during treatment and for 3 months after the last dose.
Breastfeeding
- Breastfeeding is not recommended during amivantamab treatment and for 3 months after the last dose, because the antibody may pass into breast milk and cause serious harm to a nursing infant.
Geriatrics
- Older adults, particularly those 65 and older, have experienced higher rates of severe and serious adverse reactions and treatment discontinuation compared with younger patients.
- No dose adjustment based on age alone is required, but closer monitoring for adverse reactions is reasonable in older patients.
Pediatrics
- Amivantamab has not been studied in children, and safety and effectiveness in pediatric patients have not been established.
Dosage & Administration
- Amivantamab is given as an intravenous infusion by a healthcare professional in a setting equipped to manage infusion reactions.
- The first dose is split over two consecutive days (Day 1 and Day 2) in Week 1, followed by once-weekly infusions through Week 4.
- When combined with lazertinib or used alone, dosing continues every 2 weeks starting at Week 5; when combined with carboplatin and pemetrexed, there is no dose in Weeks 5-6 and dosing resumes every 3 weeks starting Week 7.
- The dose depends on body weight at baseline (below 80 kg versus 80 kg or more), with higher total doses used for heavier patients; dose is not adjusted for later weight changes.
- Premedications, including an antihistamine, an antipyretic (fever reducer), and a corticosteroid, are required before infusions to reduce the risk of infusion reactions, with oral dexamethasone started two days before the very first infusion.
- Doses are reduced in a stepwise fashion for adverse reactions such as skin, nail, or infusion reactions, following a fixed dose-reduction schedule; treatment is permanently stopped if a third reduction would be needed.
- No dose adjustment is required for mild to moderate kidney or liver impairment, though data in more severe impairment are limited.
- If a planned dose is missed, it should be given as soon as possible with the schedule adjusted to maintain the treatment interval.
Overdose
If overdose is suspected, seek emergency medical attention immediately or contact your regional Poison Control Centre without delay.
- No specific overdose data are available for amivantamab from clinical experience.
- There is no known antidote for amivantamab overdose.
- Management involves stopping the infusion and closely monitoring the patient for adverse reactions.
- General supportive measures should continue until any toxicity resolves.
Common side effects
- Skin rash, including acne-like breakouts, may occur.
- Paronychia (painful inflammation around the nails) is very common.
- Dry skin may occur.
- Itching (pruritus) may occur.
- Mouth sores or inflammation (stomatitis) may occur.
- Nausea may occur.
- Diarrhea may occur.
- Constipation may occur.
- Vomiting may occur.
- Swelling (edema), often in the legs or around the eyes, may occur.
- Fatigue may occur.
- Decreased appetite may occur.
- Numbness or tingling (paresthesia) may occur.
- Muscle or joint pain may occur.
- Headache and dizziness may occur.
- Elevated liver enzymes may be seen on blood tests.
- Low blood albumin (hypoalbuminemia) may be seen on blood tests.
Serious side effects
Serious side effects require immediate discussion with the prescriber or emergency care.
- Infusion-related reactions, including chills, nausea, shortness of breath, flushing, chest discomfort, and low blood pressure, are common and usually occur with the first infusion.
- Interstitial lung disease or pneumonitis (lung inflammation), which can be fatal, may occur and requires prompt evaluation of any new cough, fever, or shortness of breath.
- Blood clots, including deep vein thrombosis and pulmonary embolism, occur frequently, especially when amivantamab is combined with lazertinib.
- Severe skin and nail reactions, including toxic epidermal necrolysis, may occur.
- Eye problems, including keratitis and other inflammatory or visual disturbances, may occur and require prompt referral to an eye specialist if symptoms worsen.
- Reduced heart pumping function (left ventricular dysfunction) or heart failure symptoms may occur, particularly when combined with lazertinib.
- Low white blood cell counts (neutropenia) and low platelet counts may occur, especially when combined with chemotherapy, increasing infection and bleeding risk.
- Seek urgent medical attention for severe shortness of breath, chest pain, signs of a blood clot (leg swelling, pain), sudden vision changes, or a severe skin reaction with blistering or peeling.
Use with caution
- Use with caution in patients with pre-existing lung disease, given the risk of interstitial lung disease.
- Use with caution in patients with cardiac risk factors or conditions affecting heart pumping function, particularly when combined with lazertinib.
- Use with caution in patients at elevated risk for blood clots; preventive blood thinners are often recommended for the first four months of combination treatment with lazertinib.
- Use with caution in patients who wear contact lenses, as eye irritation may require temporary discontinuation of lens use.
- Use with caution in patients with any history of severe infusion reactions to biologic therapies.
- Monitor liver enzymes, albumin, and blood counts periodically during treatment.
- Use caution when driving or operating machinery if fatigue, dizziness, or visual disturbances occur.
Contraindications
- Contraindicated in patients with known hypersensitivity to amivantamab or to any ingredient in the formulation.
Drug interactions
- No formal drug-drug interaction studies have been conducted with amivantamab.
- When combined with lazertinib, the combined regimen carries additive risks of blood clots and reduced heart pumping function that require coordinated monitoring.
- When combined with carboplatin and pemetrexed, the combination increases the risk of low blood counts (neutropenia, thrombocytopenia, anemia) beyond what either therapy causes alone.
- Anticoagulant medications used to treat or prevent blood clots during amivantamab therapy should be selected and monitored carefully, avoiding vitamin K antagonists such as warfarin where possible.
- Live or live-attenuated vaccines should be discussed with the treating oncologist before administration during therapy.
Food interactions
- No specific food interactions have been identified, as amivantamab is given by intravenous infusion and is not affected by oral intake.
Time of administration
- Amivantamab is administered only by intravenous infusion in a clinic or hospital setting on the prescribed weekly-to-extended schedule; it is not a medication the patient takes at home.
- Premedications must be given within specific windows before each infusion, as directed by the treating team.
Storage
- Unopened vials are stored refrigerated at 2°C to 8°C, protected from light, and must not be frozen.
- Once diluted for infusion, the solution should be administered within 10 hours if kept at room temperature, as directed by the healthcare team; storage and handling are managed entirely by clinic or hospital staff.
Patient take-away
- Amivantamab is a cancer therapy given by infusion in a clinic, used for specific EGFR-mutated lung cancers, and requires premedication to reduce reaction risk.
- Report any new shortness of breath, cough, fever, swelling, or skin/nail changes to your care team promptly.
- Effective contraception is needed during treatment and for 3 months afterward for patients and partners of childbearing potential.
- Keep all scheduled infusion and monitoring appointments, since dosing follows a strict weekly-to-extended interval schedule.